disitamab vedotin
Sponsor Pfizer INC · listed as PFE
disitamab vedotin is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 29, 2027 (day precision, medium confidence), tied to trial NCT05911295. That trial is in Phase 3 and currently active not recruiting, studying Urothelial Carcinoma. It appears across 7 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for disitamab vedotin in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05980481 | Phase 2/3 | Active, not recruiting | 2025-07-10 | Experimental | RemeGen Co., Ltd. | Gastric Cancer |
| NCT06221748 | Phase 2/3 | Recruiting | 2026-12 | Experimental | RemeGen Co., Ltd. | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma |
| NCT05302284 | Phase 3 | Recruiting | 2026-12-31 | Experimental | RemeGen Co., Ltd. | Urothelial Carcinoma; HER2-expressing |
| NCT05911295 catalyst | Phase 3 | Active, not recruiting | 2027-01-29 | Experimental | Seagen, a wholly owned subsidiary of Pfizer | Urothelial Carcinoma |
| NCT04400695 | Phase 3 | Recruiting | 2027-12-31 | Experimental | RemeGen Co., Ltd. | Breast Cancer |
| NCT07498907 | Phase 3 | Recruiting | 2029-05-01 | Experimental | Peking University First Hospital | Upper Tract Urothelial Carcinoma |
| NCT07315750 | Phase 3 | Recruiting | 2029-06-30 | Experimental | RemeGen Co., Ltd. | Gastric Carcinoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts